Pathology-Anatomic and Clinical·Galveston, TX

University of Texas Medical Branch Hospitals

Signal lift53%79%+26 pp with a signal here
Allocate signal →Track an away here25-26 cycle · applicant-level
Step 2 invited
229–265
p10 – p90
Sample N
523
applicants this cycle
This cycle
no tracked aways yet
Match rate
1.0%
5 of 73 applicants
01Cohort funnelthis cycle
N = 523
Applied
523
100.0%
Invited
73
14%
Class size
5
1%
J-1 visaCategoricalResearch
Your fitUniversity of Texas Medical Branch Hospitals Program

Create a free profile to see your personalized fit

Get started
Applicant profile2025 data

What successful applicants at this program look like.

See how competitive you are here

Compare your stats against applicants at University of Texas Medical Branch Hospitals Program

Create free account
Contact
JO
Program Director
Juan Pablo Olano, MD
Email director
HT
Program Coordinator
Hannah Tran
Email coordinator
Training sites2 hospitals
  • 1
    University of Texas Medical Branch Hospitals
    Galveston, TX
    Primary
  • 2
    Houston Methodist Hospital
    Houston, TX
    Participant
Score rangesinvited cohort
USMLE Step 2 CK229265
180205230255280

Level 2 CE data not available

Interview rates
US MD
47%
US DO
35%
US IMG
6%
Non-US IMG
5%
Applicant origin
In-state
65%
Out-of-state
11%
Interview prepPathology-Anatomic and Clinical
personalTell me about yourself.★ common
specialtyWhy did you choose this specialty?★ common
programWhy are you interested in our program?★ common
behavioralWhat are your strengths and weaknesses?★ common
personalWhere do you see yourself in 5-10 years?★ common
Save this program

Add University of Texas Medical Branch Hospitals to your list

Build a personal match list. Compare programs side-by-side, see how your timing stacks against peers, and get notified when peers hear back.

Next

Calculate your match probability for Pathology-Anatomic and Clinical.

See how your profile compares across all programs.

Open calculator →

Data from NRMP 2025 Residency Explorer. Not medical advice. © 2026 Rezumab LLC.